We could have a vaccine in hand this year.
Novavax’s vaccine just generated promising immune response in early trials.
In fact, according to CNBC:
“The vaccine produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and killer T-cells. Additionally, the neutralizing antibodies that were produced were higher than those seen in people who have recovered from COVID-19. The immune response was also stronger for those who had the adjuvant, the company said. Novavax said the vaccine was well tolerated with no serious adverse events reported.”
However, it’s not the only vaccine company making headlines today.
Moderna Inc. (MRNA)
Moderna is in talks with multiple countries to supply them with a potential vaccine. To date, the company has already received $400 million in deposits for it. Better, it’s expecting Phase 3 trial results with 30,000 participants as early as October 2020.
“The second quarter marked a new growth phase for Moderna as we started to build our commercial team, a historic moment for those of us who have worked at the company for many years since it was a breakthrough research enterprise. We would like to thank the entire Moderna team for their commitment to our mission of delivering on a new class of medicines for patients,” said Stéphane Bancel, Moderna’s CEO.
“In the second quarter, we began discussions with several countries for supply agreements for mRNA-1273 and as of July 31, we have received approximately $400 million of customer deposits for potential supply. As we pivot to a commercial stage company, we recognize the need for responsible pricing in the face of the pandemic. We look forward to continuing our progress as we prepare for the Phase 3 readout and the expected subsequent filing of our BLA.”
Pfizer (PFE) and BioNTech (BNTX)
Pfizer and BioNTech just noted they would provide 120 million doses of vaccine from their BNT162 development program, pending approval, to Japan’s Ministry of Health, Labor and Welfare, in the first half of 2021. The two also signed a deal with the U.S. to supply 100 million doses of vaccine for $1.95 billion.
The post The Top 4 COVID-19 Stocks with More Upside appeared first on Morningology.
